On October 21, 2026 Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), reported that the first patient has been dosed in its Phase 1 trial of STRO-006 in patients with a range of solid tumors. STRO-006 is the Company’s potential best-in-class integrin β6 (ITGB6)-targeting exatecan ADC with a drug-to-antibody ratio of 8 (DAR8), engineered for optimized pharmacokinetics, tolerability and a differentiated therapeutic index.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Dosing the first patient with STRO-006 marks our second ADC to enter the clinic in less than a year and reflects the Sutro team’s exceptional execution of our pipeline strategy," said Jane Chung, Chief Executive Officer of Sutro. "ITGB6 is difficult to target due to complex biology and is expressed across a broad range of tumors with high unmet need, including non-small cell lung and head and neck cancers. In preclinical models, STRO-006 demonstrated potent, sustained anti-tumor activity with minimal on-target toxicity, supporting our belief that Sutro’s advanced design capabilities can widen the therapeutic index and deliver a differentiated safety and efficacy profile. We look forward to advancing STRO-006 in the clinic and evaluating its potential to benefit patients."
The Phase 1, open-label, multicenter trial is designed to evaluate the safety, pharmacokinetics and preliminary anti-tumor activity of STRO-006 in adults with advanced or metastatic solid tumors. The dose-escalation portion will enroll patients with ITGB6-expressing tumor types, including head and neck cancer, non-small cell lung cancer, esophageal/gastric cancer, colorectal cancer, endometrial cancer, urothelial cancer and breast cancer. The trial will evaluate STRO-006 across ascending dose levels beginning at 1.5 mg/kg. This starting dose is enabled by Sutro’s precise design capabilities and supported by the tolerability observed in non-human primates at doses up to 30 mg/kg.
More information can be found at: View Source
About STRO-006
STRO-006 is Sutro’s next-generation DAR8 ADC targeting integrin β6 (ITGB6), a tumor-associated antigen expressed across several high-prevalence solid tumors. This candidate delivers a potent exatecan payload attached via a site-specific β-glucuronidase cleavable linker to a high-affinity antibody that binds to ITGB6 without disrupting TGFβ signaling. STRO-006 is designed to deliver a wider therapeutic index than conventional ADCs by enhancing selectivity, stability, and pharmacokinetics. In preclinical studies, STRO-006 demonstrated strong and durable anti-tumor activity. STRO-006 is currently being evaluated in a Phase 1 trial in patients with a range of ITGB6-expressing solid tumors.
(Press release, Sutro Biopharma, OCT 21, 2026, View Source [SID1234673644])